222 related articles for article (PubMed ID: 26559293)
1. Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.
Liu W; Fu Q; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
Medicine (Baltimore); 2015 Nov; 94(45):e2004. PubMed ID: 26559293
[TBL] [Abstract][Full Text] [Related]
2. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Laba P; Wang J; Zhang J
BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
[TBL] [Abstract][Full Text] [Related]
3. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
[TBL] [Abstract][Full Text] [Related]
4. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
[TBL] [Abstract][Full Text] [Related]
5. Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.
Qu Y; Liu L; Wang J; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
Oncotarget; 2016 Dec; 7(51):84775-84784. PubMed ID: 27713173
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma.
Liu W; Liu Y; Fu Q; Zhou L; Chang Y; Xu L; Zhang W; Xu J
Oncotarget; 2016 Mar; 7(12):13976-83. PubMed ID: 26910919
[TBL] [Abstract][Full Text] [Related]
7. Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Tong P; Wang J; Castle EP; Stanton ML; Cheville JC; Jonasch E; Brugarolas J; Parker AS
Mod Pathol; 2016 Jan; 29(1):34-42. PubMed ID: 26516698
[TBL] [Abstract][Full Text] [Related]
8. High Expression of Stearoyl-CoA Desaturase 1 Predicts Poor Prognosis in Patients with Clear-Cell Renal Cell Carcinoma.
Wang J; Xu Y; Zhu L; Zou Y; Kong W; Dong B; Huang J; Chen Y; Xue W; Huang Y; Zhang J
PLoS One; 2016; 11(11):e0166231. PubMed ID: 27861513
[TBL] [Abstract][Full Text] [Related]
9. Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma.
Wu Q; Yang L; Liu H; Zhang W; Le X; Xu J
Ann Surg Oncol; 2015 Jul; 22(7):2446-53. PubMed ID: 25391266
[TBL] [Abstract][Full Text] [Related]
10. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
[TBL] [Abstract][Full Text] [Related]
11. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
[TBL] [Abstract][Full Text] [Related]
12. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of CTR2 predicts poor prognosis of patients with clear cell renal cell carcinoma.
Xia Y; Liu L; Long Q; Bai Q; Wang J; Xu J; Guo J
Urol Oncol; 2016 Jan; 34(1):5.e1-9. PubMed ID: 26411550
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
[TBL] [Abstract][Full Text] [Related]
15. High mucin-7 expression is an independent predictor of adverse clinical outcomes in patients with clear-cell renal cell carcinoma.
NguyenHoang S; Liu Y; Xu L; Chang Y; Zhou L; Liu Z; Lin Z; Xu J
Tumour Biol; 2016 Nov; 37(11):15193-15201. PubMed ID: 27683054
[TBL] [Abstract][Full Text] [Related]
16.
Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
[TBL] [Abstract][Full Text] [Related]
17. High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma.
Pan D; Xu L; Liu H; Zhang W; Liu W; Liu Y; Fu Q; Xu J
Cancer Sci; 2015 May; 106(5):592-7. PubMed ID: 25702890
[TBL] [Abstract][Full Text] [Related]
18. IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma.
Wang Z; Xu L; Chang Y; Zhou L; Fu H; Zhang W; Yang Y; Xu J
Tumour Biol; 2016 Aug; 37(8):11127-34. PubMed ID: 26926076
[TBL] [Abstract][Full Text] [Related]
19. Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma.
Chang Y; Xu L; An H; Fu Q; Chen L; Lin Z; Xu J
Int J Clin Exp Pathol; 2015; 8(2):1594-603. PubMed ID: 25973044
[TBL] [Abstract][Full Text] [Related]
20. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
